PT3436019T - (1s,4s)-4-(2-(((3s,4r)-3-fluorotetra-hidro-2h-piran-4- il)amino)-8-((2,4,6-triclorofenil)amino)-9h-purin-9-il)-1- metilciclo-hexano-1-carboxamida e métodos de utilização dos mesmos - Google Patents

(1s,4s)-4-(2-(((3s,4r)-3-fluorotetra-hidro-2h-piran-4- il)amino)-8-((2,4,6-triclorofenil)amino)-9h-purin-9-il)-1- metilciclo-hexano-1-carboxamida e métodos de utilização dos mesmos

Info

Publication number
PT3436019T
PT3436019T PT177767431T PT17776743T PT3436019T PT 3436019 T PT3436019 T PT 3436019T PT 177767431 T PT177767431 T PT 177767431T PT 17776743 T PT17776743 T PT 17776743T PT 3436019 T PT3436019 T PT 3436019T
Authority
PT
Portugal
Prior art keywords
amino
fluorotetrahydro
purin
trichlorophenyl
methylcyclohexane
Prior art date
Application number
PT177767431T
Other languages
English (en)
Original Assignee
Signal Pharm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Signal Pharm Llc filed Critical Signal Pharm Llc
Publication of PT3436019T publication Critical patent/PT3436019T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
PT177767431T 2016-04-01 2017-03-31 (1s,4s)-4-(2-(((3s,4r)-3-fluorotetra-hidro-2h-piran-4- il)amino)-8-((2,4,6-triclorofenil)amino)-9h-purin-9-il)-1- metilciclo-hexano-1-carboxamida e métodos de utilização dos mesmos PT3436019T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662317468P 2016-04-01 2016-04-01

Publications (1)

Publication Number Publication Date
PT3436019T true PT3436019T (pt) 2021-11-04

Family

ID=59960229

Family Applications (1)

Application Number Title Priority Date Filing Date
PT177767431T PT3436019T (pt) 2016-04-01 2017-03-31 (1s,4s)-4-(2-(((3s,4r)-3-fluorotetra-hidro-2h-piran-4- il)amino)-8-((2,4,6-triclorofenil)amino)-9h-purin-9-il)-1- metilciclo-hexano-1-carboxamida e métodos de utilização dos mesmos

Country Status (18)

Country Link
US (2) US10047090B2 (pt)
EP (2) EP3845536A1 (pt)
JP (1) JP6995058B2 (pt)
CN (1) CN109819649B (pt)
AU (1) AU2017240050B2 (pt)
CA (1) CA3019105A1 (pt)
CY (1) CY1124677T1 (pt)
DK (1) DK3436019T3 (pt)
ES (1) ES2895419T3 (pt)
HR (1) HRP20211546T1 (pt)
HU (1) HUE056631T2 (pt)
LT (1) LT3436019T (pt)
MX (1) MX2018011970A (pt)
PL (1) PL3436019T3 (pt)
PT (1) PT3436019T (pt)
RS (1) RS62496B1 (pt)
SI (1) SI3436019T1 (pt)
WO (1) WO2017173218A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201629063A (zh) 2014-10-06 2016-08-16 標誌製藥公司 經取代胺基嘌呤化合物、其組合物及用其之治療方法
CN109069512B (zh) * 2016-04-01 2022-06-14 西格诺药品有限公司 取代的氨基嘌呤化合物、其组合物以及相关治疗方法
EP3798224A1 (en) * 2016-06-21 2021-03-31 Teva Pharmaceuticals International GmbH Solid state forms of ixazomib citrate
KR20200061363A (ko) * 2017-10-04 2020-06-02 셀진 코포레이션 시스-4-[2-｛[(3ｓ,4ｒ)-3-플루오로옥산-4-일]아미노｝-8-(2,4,6-트리클로로아닐리노)-9ｈ-퓨린-9-일]-1-메틸사이클로헥산-1-카르복스아미드의 제조 공정
AU2018345647A1 (en) 2017-10-04 2020-04-16 Celgene Corporation Compositions and methods of use of cis-4-(2-{((3S,4R)-3-fluorooxan-4-yl) amino}-8-(2,4,6-trichloroanilino)-9H-purin-9-yl)-1-methylcyclohexane-1-carboxamide

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5391485A (en) 1985-08-06 1995-02-21 Immunex Corporation DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
JPS63500636A (ja) 1985-08-23 1988-03-10 麒麟麦酒株式会社 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
IL99699A (en) 1990-10-10 2002-04-21 Autoimmune Inc Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
FI109088B (fi) 1997-09-19 2002-05-31 Leiras Oy Tabletti ja menetelmä sen valmistamiseksi
US7723340B2 (en) 2005-01-13 2010-05-25 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
US7759342B2 (en) 2005-01-13 2010-07-20 Signal Pharmaceuticals, Llc Methods of treatment and prevention using haloaryl substituted aminopurines
US7521446B2 (en) 2005-01-13 2009-04-21 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
EP1951693A4 (en) 2005-11-18 2012-05-30 Astrazeneca Ab SOLID FORMULATIONS
TWI398252B (zh) 2006-05-26 2013-06-11 Novartis Ag 吡咯并嘧啶化合物及其用途
EP2615091B1 (en) 2006-10-27 2016-01-20 Signal Pharmaceuticals, LLC Solid forms comprising 4-[9-(3S)-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluoro-phenylamino)-9H-purin-2-ylamino]-trans-cyclohexan-1-ol, compositions thereof, and uses therewith
PT2279731E (pt) 2008-04-23 2013-08-30 Farmasierra Mfg S L Composição farmacêutica melhorada contendo ibuprofeno e codeína
US20130034495A1 (en) 2009-12-09 2013-02-07 Marie Georges Beauchamps Isotopologues of 4-[9-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol
US8680076B2 (en) 2010-10-25 2014-03-25 Signal Pharmaceuticals, Llc Methods of treatment, improvement and prevention using haloaryl substituted aminopurines
US8603527B2 (en) 2010-10-25 2013-12-10 Signal Pharmaceuticals, Llc Pharmaceutical formulations of a substituted diaminopurine
US9466042B2 (en) 2012-01-24 2016-10-11 International Business Machines Corporation Facilitating the design of information technology solutions
WO2014172616A2 (en) 2013-04-18 2014-10-23 President And Fellows Of Harvard College Methods, compositions and kits for promoting motor neuron survival and treating and diagnosing neurodegenerative disorders
GB201321737D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
TW201629063A (zh) 2014-10-06 2016-08-16 標誌製藥公司 經取代胺基嘌呤化合物、其組合物及用其之治療方法
CN109069512B (zh) 2016-04-01 2022-06-14 西格诺药品有限公司 取代的氨基嘌呤化合物、其组合物以及相关治疗方法

Also Published As

Publication number Publication date
EP3436019A1 (en) 2019-02-06
JP2019515889A (ja) 2019-06-13
SI3436019T1 (sl) 2021-12-31
JP6995058B2 (ja) 2022-02-21
WO2017173218A1 (en) 2017-10-05
CY1124677T1 (el) 2022-07-22
US20170283418A1 (en) 2017-10-05
AU2017240050B2 (en) 2021-12-16
EP3436019A4 (en) 2019-08-28
EP3436019B1 (en) 2021-07-28
US10047090B2 (en) 2018-08-14
PL3436019T3 (pl) 2022-01-10
RS62496B1 (sr) 2021-11-30
EP3845536A1 (en) 2021-07-07
US10513519B2 (en) 2019-12-24
HRP20211546T1 (hr) 2022-01-07
AU2017240050A1 (en) 2018-10-11
CN109819649A (zh) 2019-05-28
MX2018011970A (es) 2019-05-20
US20180362529A1 (en) 2018-12-20
HUE056631T2 (hu) 2022-02-28
LT3436019T (lt) 2021-10-25
DK3436019T3 (da) 2021-10-11
ES2895419T3 (es) 2022-02-21
CA3019105A1 (en) 2017-10-05
CN109819649B (zh) 2023-02-28

Similar Documents

Publication Publication Date Title
ZA201903932B (en) Imidazopyrazine inhibitors of bruton's tyrosine kinase
PT3436019T (pt) (1s,4s)-4-(2-(((3s,4r)-3-fluorotetra-hidro-2h-piran-4- il)amino)-8-((2,4,6-triclorofenil)amino)-9h-purin-9-il)-1- metilciclo-hexano-1-carboxamida e métodos de utilização dos mesmos
IL276515A (en) Antibodies specific to PD-L1 and methods of using them
ZA201805439B (en) Bruton's tyrosine kinase inhibitors
SG11202002947TA (en) Substituted pyrrolopyrimidine jak inhibitors and methods of making and using the same
SI3377495T1 (sl) 2-fenil-3,4-dehidropirolo(2,1-F)(1,2,4)triazinonski derivati kot zaviralci fosfodiesteraze in uporaba le-teh
IL270940B1 (en) Device and method for decorating objects
EP3558303A4 (en) AMINO ACID COMPOUNDS AND METHOD FOR USE
IL259862B (en) Inhibitors of proton tyrosine kinase and methods of using them
EP3532528A4 (en) POLYAMIDES DERIVED FROM RENEWABLE SOURCES AND PROCESSES FOR THEIR PREPARATION
EP3472306A4 (en) IDENTIFYING A FACTOR TO PROMOTE SELF-RENEWAL OF HUMAN HSC
PT3135110T (pt) Derivados de 1,7-diaril-1,6-heptadieno-3,5-diona, processos para a produção e utilização dos mesmos
ZA201902325B (en) 7-substituted 1-aryl-naphthyridine-3-carboxylic acid amides and use thereof
EP3651606A4 (en) PRECIOUS STONE COATINGS AND RELATED MANUFACTURING AND USE PROCEDURES
ZA201901593B (en) An interchangeable jewelry linking system and clasps thereof
ZA201608720B (en) Thermobaric nonel and preparation method thereof
ZA201901505B (en) Phenylalanine-free protein for the treatment of pku
ZA201903845B (en) Fgfr4 inhibitor and preparation method and use thereof
HK1248541A1 (zh) 鉤端螺旋體免疫防護蛋白及其鑒定和使用方法
ZA201903032B (en) Nail plater apparatus and related methods
SI3408264T1 (sl) Nilotinibijev dinitrat (V) in njegove kristalne oblike
IL254205B (en) Reagents for the acylation of amino acids and methods for their use
PT3512849T (pt) 1-arilnaftiridina-3-carboxamidas 7-substituídas e sua utilização
GB201705064D0 (en) Method of adjustung the length of an article
GB201622441D0 (en) Abrasive article and method of use